Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant

Infezioni in Medicina

Volumn 14, Issue 3, 2006, Pages 145-151

  Scotto, Gaetano ^a   Palumbo, Emilio ^a   Fazio, Vincenzina ^b   Cibelli, Donatella Concetta ^c   Saracino, Annalisa ^a   Angarano, Cioacchino ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Hospital of Foggia   (Italy)

^c NONE

Author keywords

Chronic hepatitis; HBV; Interferon; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CORE PROTEIN; CREATINE KINASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; MUTANT PROTEIN; VIRUS DNA;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL PANCREATITIS; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERAMYLASEMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREATITIS; PROTEIN VARIANT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION;

EID: 33846817485     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chu C.M., Liau Y.F. Natural history of chronic B virus infection: an immunophatological study. J. Gastroenterol. Hepatol. 12, S218-S222, 1997.
2. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350, 1118-1129, 2004.
3. Oliviero F., Santantonio T., Bellati G. et al. Long-term response to therapy of chronic anti-Hbe-positive hepatitis B is poor independent of type and schedule of interferon. Am. J. Gastroenterol. 94, 1366-1372, 1999.
4. van Zonneveld M., Honkoop P., Hansen B.E. et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 39, 804-810, 2004.
5. Lai C.L., Chein R.N., Leung N.W.Y. et al. A one year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339, 61-68, 1998.
6. Dienstang J.L., Schiff E.R., Wright T.L. et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256-1263, 1999.
7. Lau D.T.Y., Khokhar F., Doo E. et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 32, 828-834, 2000.
8. Santantonio T., Mazzola M., Iacovazzi T. et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 32, 300-306, 2000.
9. Tassopoulos N.C., Volpes R., Pastore G. et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology. 29, 889-896, 1999.
10. Lay C.L., Liaw Y.F. Lamivudine therapy for chronic hepatitis B infection: a 12 months placebo-controlled, double-blind, multicentre study. J. Hepatol. 3, P/CO 1/19:81, 1997.
11. Hadziyannis S.J., Papatheodoridis G.V., Dimou E. et al. Efficacy of long-term lamivudine monotherapy in patients with e antigen-negative chronic hepatitis B. Hepatology 32, 847-851, 2000.
12. Liaw Y.F., Leung N.W.Y., Chang T.T. et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119, 172-180, 2000.
13. Tatulli I., Francavilla R., Rizzo G.L. et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J. Hepatol. 35, 805-810, 2001.
14. Jaboli M.F., Roda E., Fabbri C. et al. The efficacy and safety of long-term administration of alpha-IFN and lamivudine in patients with chronic hepatitis B. Digest. Liver. Dis. 33, A24, 2001.
15. Schalm S.W., Heathcote J., Cianciara J. et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46, 562-568, 2000.
16. Barbaro G., Zechini F., Pellicelli A.M. et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter randomized trial. J. Hepatol. 35, 406-411, 2001.
17. Santantonio T., Niro G.A., Sinisi E. et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J. Hepatol. 36, 799-804, 2002.
18. Simon K., Rotter K., Zalewska M., Gladysz A. HBV DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B. Med. Sci. Monit. 6, 971-975, 2000.
19. Lok A.S., Ghany M.G., Watson G., Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA level response to interferon therapy for chronic hepatitis B. J. Viral Hepat. 5, 171-178, 1998.
20. Rang A., Gunter S., Will H. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J. Hepatol. 31, 791-799, 1999.
21. Boni C., Bertoletti A., Penna A. et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102, 968-975, 1998.